Results 221 to 230 of about 2,482,456 (261)
Some of the next articles are maybe not open access.
Autophagy as a target for anticancer therapy
Nature Reviews Clinical Oncology, 2011Autophagy is an important homeostatic cellular recycling mechanism responsible for degrading unnecessary or dysfunctional cellular organelles and proteins in all living cells. Autophagy is particularly active during metabolic stress. In the cancer cell it fulfils a dual role, having tumor-promoting and tumor-suppressing properties. Functional autophagy
Filip, Janku +3 more
openaire +2 more sources
Spermine Metabolism and Anticancer Therapy
Current Cancer Drug Targets, 2009The natural polyamines (PA), putrescine (PUT), spermidine (SPD) and spermine (SPM) are ubiquitous constituents of eukaryotic cells. The increase of PA in malignant and proliferating cells attracted the interest of scientists during last decades, addressing PA depletion as a new strategy to inhibit cell growth. Selective enzyme inhibitors were developed
Amendola, R. +5 more
openaire +2 more sources
Apoptosis and the response to anticancer therapy
Current Opinion in Oncology, 2001Apoptosis is a distinctive form of cell death that reflects cleavage of a subset of intracellular polypeptides by proteases known as caspases. Two major intracellular caspase cascades, one activated predominantly by death receptor ligands and the other triggered by various cellular stresses, including DNA damage and microtubule disruption, have been ...
B M, Mow +3 more
openaire +2 more sources
Inulin/oligofructose and anticancer therapy
British Journal of Nutrition, 2002The results of our investigations indicate that dietary treatment with inulin or oligofructose incorporated in the basal diet for experimental animals: (i) reduced the incidence of mammary tumors induced in Sprague-Dawley rats by methylnitrosourea; (ii) inhibited the growth of transplantable malignant tumors in mice; and (iii) decreased the incidence ...
H S, Taper, M B, Roberfroid
openaire +2 more sources
Docetaxel Nanotechnology in Anticancer Therapy
ChemMedChem, 2012AbstractTaxanes have been recognized as a family of very efficient anticancer drugs, but the formulation in use for the two main taxanes—Taxol for paclitaxel and Taxotere for docetaxel—have shown dramatic side effects. Whereas several new formulations for paclitaxel have recently appeared, such as Abraxane and others currently in various phases of ...
Pengxiang, Zhao, Didier, Astruc
openaire +2 more sources
PARP inhibitors for anticancer therapy
Biochemical Society Transactions, 2014PARP-1 [poly(ADP-ribose) polymerase-1], which plays a key role in DNA repair, was discovered 50 years ago. PARPi (PARP inhibitors), originally made to probe the function of the enzyme, inhibit DNA repair and increase the potency of anticancer cytotoxic agents.
openaire +3 more sources
Prodrugs in Photodynamic Anticancer Therapy
Current Pharmaceutical Design, 2011Photodynamic therapy (PDT), the concept of cancer treatment through the selective uptake of a light-sensitive agent followed by exposure to a specific wavelength, is limited by the transport of a photosensitizer (PS) to the tumor tissue. Porphyrin, an important PS class, can be used in PDT in the form of its prodrug molecule 5-aminolevulinic acid (5 ...
Robert, Musiol +2 more
openaire +2 more sources
Targeting apoptosis for anticancer therapy
Seminars in Cancer Biology, 2015Programmed cell death via apoptosis is characteristically disturbed in human cancers. This facilitates not only tumor formation and progression, but also treatment resistance. Since many currently applied anticancer treatment strategies rely on intact cell death signaling pathways for their therapeutic efficacy, a better understanding of the regulatory
openaire +2 more sources
Telomeres as targets for anticancer therapies
Expert Opinion on Therapeutic Targets, 2011The limitless replicative potential of cancer cells relies on telomere integrity (which is guaranteed by a complex interaction between several specialized proteins and telomeric DNA) and the activation of specific mechanisms for telomere length maintenance.
Marco, Folini +3 more
openaire +2 more sources
Current Topics in Medicinal Chemistry, 2005
Escherichia coli purine nucleoside phosphorylase (PNP) catalyzes the cleavage of 9-(2-deoxy-beta-D-ribofuranosyl)-6-methylpurine (MeP-dR), while human PNP does not. MeP-dR is well tolerated while the cleavage product, 6-methylpurine (MeP), is highly cytotoxic.
Yang, Zhang +3 more
openaire +2 more sources
Escherichia coli purine nucleoside phosphorylase (PNP) catalyzes the cleavage of 9-(2-deoxy-beta-D-ribofuranosyl)-6-methylpurine (MeP-dR), while human PNP does not. MeP-dR is well tolerated while the cleavage product, 6-methylpurine (MeP), is highly cytotoxic.
Yang, Zhang +3 more
openaire +2 more sources